The investigators and participants were masked to all summary results and outcomes. All data were collected, stored, and summarized off-site. Because the patients applied and removed the device and the clinicians were monitoring the patients, masking the intervention to the patients and clinicians was not feasible.
Inclusion and Exclusion Criteria
Otherwise healthy adults between the ages of 18 and 75 years, in whom moderate to severe primary RLS was diagnosed, were recruited from Erie and the surrounding locations by newspaper, television, and radio ads; flyers in the waiting room; and by the clinicians themselves.
Each patient was examined by a neurologist or 1 of the 2 podiatrists experienced in diagnosing RLS. Patients were screened using medical history, the International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria, 7 and the IRLSSG Rating Scale, a validated survey with high interexaminer reliability. 8 Inclusion criteria included the following: (1) a total score of 15 or greater on the IRLSSG Rating Scale; (2) selfreported evening and nighttime symptoms with sleep impairment due to RLS; and (3) RLS for at least 6 months with symptoms at least 2 to 3 times per week.
At least 12 and as many as 42 episodes of RLS per patient were anticipated during the study period.
Patients were excluded if they were pregnant or had any serious medical conditions, conditions that presented a safety concern, or conditions that affected efficacy assessment, such as taking medications known to affect RLS (eg, antidepressants). Disqualifying medical conditions included but were not limited to claudication; diabetes mellitus; fragile, thin skin; impaired wound healing; inability to sit still or remain motionless; injury The prevalence of RLS varies depending on geographic location, inclusion criteria, and other factors.
In the United States, the prevalence ranges from 5% to 10%. 2 With the population estimated at 306 million, the number of people in the United States with RLS ranges from 15 to 30 million, and those with moderate to severe symptoms, 9 million. Restless legs syndrome disproportionally affects women 2 ; the incidence in women is estimated to be twice as high as that in men.
Although symptoms can manifest at any age, moderate to severe cases often manifest in people middleaged or older, with symptoms increasing with increasing age. 2 In approximately 3% of people with RLS, the symptoms are so severe that they seek treatment. 3 Potent medications, such as opioids, central nervous system depressants, anticonvulsants, and dopamine agonists have been used to ease symptoms, each with adverse effects. 4, 5 Reports on the efficacy of nonpharmacologic therapies, such as sequential compression devices, are emerging. 6 An RLS device in the form of a foot wrap was designed to put adjustable targeted pressure on the abductor hallucis and the flexor hallucis brevis muscles in the foot On day 8, patients were instructed on the application of the RLS device and checked by a study administrator to ensure that the devices were correctly applied. Patients were instructed to start with slight pressure for the first hour and, if their symptoms did not resolve, to increase pressure in small increments until symptoms were alleviated. They were told to watch for circulation problems;
in case of pain, numbness, or tingling or if the foot or toes turned purple, immediate loosening or removal of the device was advised.
Patients were instructed to put the device on both feet after RLS symptoms occurred in the evening, when they were relaxing, or after they had gone to bed and only during periods B and D. The patients were instructed to remove the device after symptoms had resolved completely or in the morning, whichever came first. This restless legs syndrome device is a foot wrap that puts adjustable and continuous targeted pressure on the abductor hallucis and the flexor hallucis brevis muscles on the medial and plantar aspect of the feet. An outer cloth wrap supports and holds the pressure pad in place. The cloth wrap is held in place by hook and loop straps, which allow application and retention of adjustable pressure.
IRLSSG Rating Scale Scores
Patients Descriptive statistics were used to determine IRLSSG score means and SDs for each period. A paired t test, (α=.05) was used to determine significant differences among the groups. By calculating mean IRLSSG scores within each period, more data points were collected, decreasing variability over time (by survey days). Descriptive statistics were used to calculate the mean and SD IRLSSG score for each of the 22 survey days.
In addition, we identified studies on the use of ropinirole, a dopamine agonist, and placebo and their effects on RLS symptoms. Each ropinirole study [9] [10] [11] was examined to determine the initial, final, and change in mean IRLSSG scores for ropinirole and placebo. A meta-analysis (Meta-Analysis, Biostat) was used to combine IRLSSG scores of the 3 ropinirole and placebo arms.
These studies were all sponsored by industry and had similar demographics, inclusion and exclusion criteria, disease severity, interventions, assessment tools, and outcomes. Therefore, the heterogeneity was very low, providing a high level of confidence that these studies could be combined.
The change in mean IRLSSG scores with the RLS device was compared with the change in mean IRLSSG scores for ropinirole and placebo by meta-analysis. By comparing the changes, the effects of different length of treatment, treatment timing, and end points were negated. A 2-sample t test (α=.05) was then used to determine differences among the RLS device, ropinirole, and placebo pill.
CGI Scale
The clinicians completed 4 CGI Scales, 12 The RLS device CGI Scale scores were compared with the historic controls by χ 2 analysis (α=.05). Responders in the ropinirole studies were compared with responders in the RLS device study by χ 2 analysis (α=.05). [9] [10] [11] [12] Of note, the efficacy index and severity were not reported in the historic controls, negating comparisons.
Safety
Adverse effects were monitored and documented by the clinicians during examinations at each visit. Also, all patient-reported problems were documented. All information on all adverse effects was collected and analyzed for severity and relation to RLS device and compared with the ropinirole studies using descriptive statistics.
Outcomes

IRLSSG Rating Scale
The RLS device proved highly effective, with overall significance level. This study was a modified intent-totreat protocol. All patients were included, but some were excluded in the final analysis. To address missing data, a last observation carried forward method of accounting was used (ie, if a patient dropped out of the study before it ended, then the last observed score on the dependent variable was used for all subsequent missing observation points). A P value ≤.05 was considered statistically significant.
Results
Of 132 patients who were screened by phone, 47 were 
Adverse Effects
Seven patients had adverse effects related to the device.
These effects included pain (2), paresthesia (2), irritability (3), spasm (1), and a local complication of warm feet (1). All adverse effects resolved when the device was loosened. Other mild adverse effects reported resolved spontaneously.
Several severe and some potentially life-threatening adverse effects, including somnolence, worsening of symptoms, dosage augmentation, rebound, and nausea have been noted with dopamine agonist use. [9] [10] [11] 14, 15 The RLS device demonstrated none of the adverse effects associated with the current medications used for RLS. The adverse effects associated with medication may limit its usefulness in many patients, including those who drive or operate heavy equipment, those with mild RLS, and women who are breastfeeding.
Follow-up Survey
Seventeen of 30 patients (57%) responded to the follow-up survey ( Table 2) . At long-term follow-up, the RLS device proved highly effective, decreasing mean IRLSSG scores from severe to mild. Fourteen respondents reported their symptoms were less; 2, the same; and 1, no answer. Eleven of the 17 respondents reported no problems wearing the device. Sixteen would recommend the device. Four patients reported complete remission of symptoms; 8 reported still wearing the device, but less frequently and for a shorter duration.
Twelve respondents rated the device as either a 9 or 10 on a 10-point scale, with 10 being "best."
CGI Scale
This instrument comprises a severity scale, improvement scale, and efficacy index (adverse effects vs therapeutic efficacy). By clinician observation, 29 of 30 patients (97%) had a decrease in severity, and severity in 25 of 30 (83%) decreased 2 or more levels. All patients improved.
Symptoms were "much improved" or "very much improved" in 27 of 30 patients (90%) by the end of the study. These patients were designated as responders. Movement disrupts the contraction and produces temporary relief ( Figure 5 ).
We believe that continued pressure on the abductor hallucis and flexor hallucis brevis muscles throughout the evening signals the brain to relax rather than contract the muscles, acting as a counter-stimulant. This theory represents a new and unique mechanism of action to suppress the symptoms of RLS. Pressure produced by the RLS device on the muscles may also stimulate a
Discussion
Mechanism of Action
We theorize that patients with RLS have a mild dopamine dysfunction in the afferent nerve pathway that signals pain or irritation. The brain interprets the signals and instructs the muscles to contract. The contraction, in turn, produces pain or irritation, again signaling the brain to instruct continued or increased contraction, producing continued pain or irritation. small sample size (N=9). However, findings such as these lend support to the theory that pressure on targeted regions causes the muscles to relax, decreasing RLS.
The RLS device in the current study exemplifies the underlying philosophy of the tenets of osteopathic medicine-the body is a unit and is capable of self-healing. 16 Pressure on the foot caused responses in the brain, which, in turn, relaxed the muscles in the leg, leading to a decrease in symptoms of moderate to severe RLS.
Ropinirole Safety
After ropinirole was marketed to larger numbers of patients, the safety profile changed. Somnolence (and falling asleep while driving), rebound, and compulsive behavior became problematic, resulting in several lawsuits. 9 In many cases, prolonged medication use led to dosage tolerance, which required regular increases in the dose to manage symptoms. 14, 15 Although tolerance can occur with several medications used to treat RLS, dopamine therapy is associated specifically with dosage augmentation. 17 
Placebo Effect
A large placebo response has been observed in RLS studies, ranging from 40% to 75% in some clinical RLS trials. In the 3 ropinirole studies, the placebo pill was 75% as effective as ropinirole.
True-negative controls are lacking in most RLS studies but are needed because of the extreme placebo response. 17, 18 Excessive placebo response can confound results and, in some studies, obscure test/placebo differences when true differences exist. 18 If the RLS device responses were solely mediated by a placebo effect, the RLS devices' IRLSSG score would have improved no more than 8 points, as seen in the 3 ropinirole studies [9] [10] [11] ; instead, it improved 17 points. reported a statistically significant decrease in IRLSSG scores. Their study, which was an uncontrolled prospective study using a convenience sample of adults, had a 
Limitations
When a meta-analysis is used, several opportunities for bias exist, particularly if studies are selected that prejudice the results toward a particular conclusion. Publication bias can occur when research underrepresents the population of completed studies. Bias can be minimized when the instruments of measure are standardized, measuring specific outcomes across studies. 20 Risk of bias in a review should be assessed regardless of variability. The low heterogeneity among the 4 studies we compared diminished publication bias.
The lack of a sham device or control was a limitation. Loosening the straps to produce a sham device control could have caused a potential tripping hazard.
A study on ClinicalTrials.gov revealed that device studies using a sham were rare, representing 0.4%
(65 of 15805) of all studies reported. 19 When practical considerations prevent running a sham control, the current standard of care or best medical therapy is commonly used, which in this case, was ropinirole. 19 Because ropinirole had been extensively studied, results of 3 of the largest national and international drug trials comprising 931 patients were used as a historic control for comparison with the RLS device. [9] [10] [11] Using historic controls spared the patients exposure to a myriad of adverse effects of ropinirole.
Future studies are needed using a modified device in controlled double-blinded conditions with the incorporation of true negative controls (no placebo device or medication). Magnetic resonance imaging studies and measurement of dopamine levels would also be helpful in elucidating the mechanism of action, but those measures were beyond the scope of the current study.
Conclusion
Targeted pressure on the abductor hallucis and the flexor hallucis brevis muscles with the RLS device was almost twice as effective as historic placebo medication and 1.4 times as effective as ropinirole in lowering IRLSSG scores, with none of the adverse effects associated with current medications for RLS. Proposed mechanism of action. The restless legs syndrome device works on foot muscles, and the dopamine agonists target the brain. Both lead to the relaxation of leg muscles.
